AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.…
3 Stocks With Superb Earnings Acceleration to Buy Before 2027
AnaptysBio (NASDAQ: ANAB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 46.63 USD on 20 November 2026, up 76.4% over 52 weeks. Its 52-week range is 20.18 USD to 72.36 USD: the price is 35.6% below the high and 131.1% above the low.
At a market capitalisation of 1.39B USD, it trades at 7.2 times trailing earnings and 8.7 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 78% for ANAB.
AnaptysBio reports return on equity of -35.6%, an operating margin of 15.0% and revenue down 60.3% year over year.
Its debt exceeds its cash by 109.39M USD, a debt-to-equity ratio of 0.38. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 87.25 USD is 87.1% above the current price. The next earnings report is expected on 3 March 2027.